Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion
Merck (known as MSD outside the US and Canada) has announced that it has entered into a definitive agreement to sell its Merck Consumer Care (MCC) business to Bayer AG for $14.2 billion. Under the terms of the agreement, Bayer AG will acquire Merck’s existing OTC business, including the global trademark and prescription rights for Claritin and Afrin.
The company also announced a worldwide clinical development collaboration with Bayer to market and develop its portfolio of soluble guanylate cyclase (sGC) modulators. This includes Bayer’s Adempas (riociguat), the first member of this novel class of compounds. Adempas is approved to treat pulmonary arterial hypertension (PAH) and is the first and only drug treatment approved for patients with chronic thromboembolic pulmonary hypertension (CTEPH). Adempas is currently marketed in the US and Europe for both PAH and CTEPH and in Japan for CTEPH. The two companies will equally share costs and profits from the collaboration and implement a joint development and commercialization strategy.
“The sale of our consumer care business is part of our efforts to ensure that assets within our portfolio align with our core strategy, have industry-leading potential and generate long-term shareholder value,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “By unlocking value in Merck Consumer Care, we’re able to further our goal of being the premier research-intensive biopharmaceutical company through targeted investments that strengthen our product portfolio and enhance our pipeline.”
"Merck Consumer Care is a strong business with a portfolio of well-established product brands, such as Claritin, Afrin and Coppertone, that are leaders in their respective categories," said Dr Marijn Dekkers, Bayer AG Chairman of the Board of Management. "The combination of Merck Consumer Care's complementary portfolio of products and geographic reach with Bayer's will create a global consumer care business better positioned to serve consumers around the world. We look forward to having the talents of the Merck team, with their track record of innovation, joining our strong Consumer Care team at Bayer HealthCare."
The collaboration also includes clinical development of vericiguat (BAY102), which is currently in Phase II trials for worsening heart failure, as well as opt-in rights for other early-stage sGC compounds in development at Bayer. Merck will in turn make available its early- stage sGC compounds under similar terms.
In return for these broad collaboration rights, Bayer will receive a $1 billion up-front payment with the potential for additional milestone payments upon the achievement of agreed- upon sales goals. For Adempas, Bayer will continue to lead commercialization in the Americas, while Merck will lead commercialization in the rest of the world (ROW). For vericiguat and other potential opt-in products, Bayer will lead in the ROW and Merck will lead in the Americas. For all products and candidates included in the agreement, both companies will share in development costs and profits on sales and will have the right to co-promote in territories where they are not the lead.
Merck expects after-tax proceeds from the sale of MCC to be between $8 and $9 billion. The company will use the after-tax proceeds — consistent with its capital allocation strategy — to resource those areas within its business that represent the highest potential growth opportunities, such as MK-3475, to augment the company's pipeline with external assets that can create value and to continue to provide an industry-leading return of capital to shareholders.
“Both Merck and Bayer have a rich history of developing and commercializing innovative products to meet significant unmet medical needs,” said Frazier. “Our collaboration with Bayer builds on our respective strengths, and we look forward to working with Bayer in the field of sGC modulators.
“The value we obtained for our consumer business is a tribute to our colleagues who have built an outstanding business with a talented team and trusted, well-known product brands,” said Frazier. “We know the strengths of our team will serve Bayer well.”
Merck expects to close the sale of MCC in second half of 2014, subject to customary closing conditions, including regulatory approvals. The company plans to update its 2014 financial guidance when the transaction closes.
Related News
-
News Women in Pharma: Hiring Across the Gender Divide
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News Revolutionising cancer treatment with mRNA-based therapeutics
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours. -
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ... -
News Choosing the Right CDMO Partner: A Comprehensive Guide
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance